Trial Profile
Phase II Study of ZK 219477 in Patients With Recurrent Glioblastoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Sagopilone (Primary)
- Indications Glioblastoma
- Focus Biomarker; Therapeutic Use
- 21 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Jul 2012 Additional trial locations identified as reported by European Clinical Trials Database.
- 07 Sep 2007 Status change from recruiting to in progress